DE EN Anmelden

In your studies 'Drug Regulator Affairs'

©Volker Lannert / Universität Bonn

Master's thesis


As part of the continuing education Master's degree programme, Master's theses are written on relevant topics in the field of 'Drug Regulatory Affairs' using scientific methods. The topics are highly topical, diverse and the results are both of interest in a scientific context and relevant to many areas of activity in 'Drug Regulatory Affairs'.

Here you will find all Master's theses written since the year 2000, including the title and a summary. In this collection, many Master's theses can also be viewed and downloaded in full text.

Further information on Master's theses (e.g. registration, processing) can be found in our ‘Master's thesis guidelines/Leitfaden für die Anfertigung einer Masterarbeit’ (in German) and in the ‘Information leaflet - Master's thesis’ at

Downloads from A-Z

Do you have any questions or are you interested in the full text of a Master's thesis that is not listed here?
Please feel free to contact me.

Dr. Jasmin Fahnenstich

Dr. Jasmin Fahnenstich

Study programme manager

Phone: +49 (0) 228 - 9268 6806

Send e-mail

Master's thesis

The collection of Master's theses can be searched and sorted by entering keywords.

Year Name Title Full text Summary
2018 Andres Rodriguez Lüdke Assessment of Plants as Raw Materials / Resources for the Production of Medicinal Products in a Globalized Environment
2018 Dr. Helen Springer-Frauenhoff Life Cycle of CAR -T cell products: Legal framework and points to consider during the life of a CAR-T cell product
2018 Dr. Petra Starck-Lantová The role of animal studies in declining efficiency of pharmaceutical research and development from the regulatory perspective ***
2018 Theodor Tiko The regulatory landscape of human microbiome modulation using live microorganisms in the EU and US ***
2018 Theresa Vavvas Polycyclic aromatic hydrocarbons in (traditional) herbal medicinal products
2018 Sandra Wagner Evaluation of Carcinogenicity Studies of Medicinal Products for Human Use authorized via the Centralized Procedure (2010 - 2017) ***
2018 Dr. Christopher Weber Regulatory environment for defined post-approval CMC Quality Control method changes of Biologics worldwide and implications for a suitable MAH change management
2018 Dr. Annika Wedeking US Regulation of Promotional Materials for Prescription Drugs: a Regulatory Perspective ***
2018 Dr. Elmar Wegener Real World Evidence - Impact on Regulatory Decision Making ***
2018 Dr. Stefan Werner Erörterung der Erstattungsfähigkeit von Flüssigbiopsie-Verfahren in Deutschland
2018 Patricia Westendorf How to update a CEP? An analysis of the regulatory activities in a middle-sized pharmaceutical company, taking account of the new Q&A of the EMA ***
2018 Angela Zambrano Global regulatory dynamics in response to the challenges of innovation in gene and cell therapy products: An overview
2017 Stefan Brunkhorst The Prescription Status and Its Implications for Pharmaceutical Companies ***
2017 Alice Burger Comparison of Pharmacovigilance in Germany and Japan ***
2017 Monica Cano History of attention deficit and hyperactivity disorder linked to Methylphenidate: A regulatory overview of the product lifecycle
2017 Dr. Thi Hong Nhung Do Options of innovative vaccine approval without human efficacy data ***
2017 Dr. Valeria Facchinetti Toward expanded patient access to gene and cell therapy products: a comparative study of the regulatory approaches in the European Union, the United States and Japan ***
2017 André Fischer The Swiss Überprüfungsverfahren – Similarities and differences to the EU Referral procedure ***
2017 Gabriele Gempel-Drey Medicinal products for geriatric patients in Germany - Current status of regulatory requirements and clinical reality ***
2017 Cordula Grandpierre-Verhees The challenge of filing a drug application for an NCE for human use for the US and EU in parallel - An overview of the potential differences between the US and EU CTD dossiers and essential pre-application activities
  • Total: 959